<DOC>
	<DOC>NCT01595958</DOC>
	<brief_summary>The investigators hypothesised that cyclosporine A administration at the onset of cardiopulmonary resuscitation, by inhibiting the mitochondrial permeability transition pore, could prevent the post cardiac arrest syndrome and improve outcomes.</brief_summary>
	<brief_title>Cyclosporine A in Cardiac Arrest</brief_title>
	<detailed_description />
	<mesh_term>Heart Arrest</mesh_term>
	<mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Witnessed outofhospital cardiac arrest Non shockable cardiac rhythm Evidence of trauma Evidence of pregnancy Duration of no flow more than 30 minutes Rapidly fatal underlying disease Allergy to cyclosporin A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Cardiac arrest</keyword>
	<keyword>heart arrest</keyword>
	<keyword>cyclosporine A</keyword>
	<keyword>post cardiac arrest syndrome</keyword>
	<keyword>protective agent</keyword>
	<keyword>multiple organ failure</keyword>
	<keyword>mitochondrial permeability transition pore</keyword>
	<keyword>mitochondria</keyword>
	<keyword>cardio-pulmonary resuscitation</keyword>
	<keyword>cardioprotection</keyword>
	<keyword>ischemia reperfusion</keyword>
	<keyword>postconditioning</keyword>
</DOC>